EcoDrugPlus

Uncharacterized Loc113021108

Ensembl ID : ENSACLG00000011688
Gene Symbol: LOC113021108
2 Cross references
194 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSACLG00000020050
Gene Symbol: UTS2R
4 Cross references
92 Possible Orthologues:

Utrophin

Ensembl ID : ENSACLG00000018227
Gene Symbol: UTRN
2 Cross references
253 Possible Orthologues:

V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog

Ensembl ID : ENSACLG00000027677
Gene Symbol: KRAS
1 Cross references
209 Possible Orthologues:

V-Rel Avian Reticuloendotheliosis Viral Oncogene Homolog A

Ensembl ID : ENSACLG00000012132
Gene Symbol: RELA
1 Cross references
201 Possible Orthologues:

Vascular Endothelial Growth Factor A

Ensembl ID : ENSACLG00000008575
Gene Symbol: VEGFA
3 Cross references
198 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSACLG00000014083
Gene Symbol: VDR
3 Cross references
392 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSACLG00000008953
Gene Symbol: LOC113022716
3 Cross references
394 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1-Like

Ensembl ID : ENSACLG00000006943
Gene Symbol: LOC113019296
3 Cross references
191 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSACLG00000020193
Gene Symbol: LOC113022429
3 Cross references
212 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSACLG00000000361
Gene Symbol: LOC113024426
2 Cross references
193 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSACLG00000016387
Gene Symbol: LOC113014747
3 Cross references
168 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).